Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
11 Apr 24
DEFA14A
Additional proxy soliciting materials
11 Apr 24
DEF 14A
Definitive proxy
11 Apr 24
PRE 14A
Preliminary proxy
1 Apr 24
8-K
Other Events
1 Apr 24
S-8
Registration of securities for employees
25 Mar 24
10-K
2023 FY
Annual report
25 Mar 24
8-K
Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights
25 Mar 24
8-K
Departure of Directors or Certain Officers
8 Mar 24
8-K
Results of Operations and Financial Condition
23 Feb 24
424B5
Prospectus supplement for primary offering
23 Feb 24
8-K
Other Events
22 Feb 24
8-K
Other Events
21 Dec 23
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K
Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology
8 Nov 23
8-K
Regulation FD Disclosure
16 Oct 23
8-K
Entry into a Material Definitive Agreement
5 Oct 23
424B5
Prospectus supplement for primary offering
5 Oct 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
8-K
Equillium Reports Second Quarter 2023 Financial Results and Provides Corporate and Clinical Updates
9 Aug 23
8-K
Termination of a Material Definitive Agreement
25 May 23
8-K
Submission of Matters to a Vote of Security Holders
23 May 23
10-Q
2023 Q1
Quarterly report
11 May 23
8-K
Equillium Reports First Quarter 2023 Financial Results and Provides Clinical Updates
11 May 23
ARS
2022 FY
Annual report to shareholders
13 Apr 23
DEFA14A
Additional proxy soliciting materials
13 Apr 23
DEF 14A
Definitive proxy
11 Apr 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
6 Apr 23
PRE 14A
Preliminary proxy
31 Mar 23
10-K
2022 FY
Annual report
23 Mar 23
8-K
Equillium Reports Fourth Quarter and Full Year 2022 Financial Results and Provides CorporateĀ & Clinical Development Updates
23 Mar 23
RW
Registration withdrawal request
23 Feb 23
EFFECT
Notice of effectiveness
19 Jan 23
CORRESP
Correspondence with SEC
13 Jan 23
UPLOAD
Letter from SEC
12 Jan 23
S-8
Registration of securities for employees
6 Jan 23
S-3
Shelf registration
6 Jan 23
8-K
Equillium and Metacrine Mutually Agree to Terminate Definitive Merger Agreement
23 Dec 22
425
Business combination disclosure
14 Dec 22
8-K
Other Events
14 Dec 22
Latest ownership filings
3
Penny Tom
8 Mar 24
SC 13G
TAKEDA PHARMACEUTICAL CO LTD
19 Jan 24
4
DANIEL BRADBURY
3 Jan 24
4
Bruce D. Steel
3 Jan 24
4
Stephen Connelly
3 Jan 24
4
Joel Rothman
3 Jan 24
4
Christine Zedelmayer
3 Jan 24
4
Jason A Keyes
3 Jan 24
4
Yu (Katherine) Xu
23 May 23
4
Barbara Troupin
23 May 23
4
Mark Pruzanski
23 May 23
4
Charles Douglas McDermott
23 May 23
4
BALA S MANIAN
23 May 23
4
MARTHA J DEMSKI
23 May 23
SC 13G/A
VICTORY CAPITAL MANAGEMENT INC
3 Mar 23
4
DANIEL BRADBURY
7 Feb 23
4
Stephen Connelly
7 Feb 23
4
Jason A Keyes
7 Feb 23
4
Joel Rothman
7 Feb 23
4
Bruce D. Steel
7 Feb 23
4
Christine Zedelmayer
7 Feb 23
SC 13G/A
VICTORY CAPITAL MANAGEMENT INC
31 Jan 23
4
DANIEL BRADBURY
4 Jan 23
4
Stephen Connelly
4 Jan 23
4
Jason A Keyes
4 Jan 23
4
Joel Rothman
4 Jan 23
4
Bruce D. Steel
4 Jan 23
4
Christine Zedelmayer
4 Jan 23
4
Jason A Keyes
30 Aug 22
4
Jason A Keyes
6 Jun 22
4
Yu (Katherine) Xu
25 May 22
4
Mark Pruzanski
25 May 22
4
Charles Douglas McDermott
25 May 22
4
BALA S MANIAN
25 May 22
4
MARTHA J DEMSKI
25 May 22
4
Jason A Keyes
5 Apr 22
4
Barbara Troupin
8 Mar 22
3
Barbara Troupin
8 Mar 22
SC 13G
Decheng Capital Management III (Cayman), LLC
14 Feb 22
SC 13G/A
VICTORY CAPITAL MANAGEMENT INC
1 Feb 22